{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:06:43Z","timestamp":1789718803053,"version":"4.0.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS) database and to provide reference for safe clinical drug use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The adverse events report data of oxaliplatin from the first quarter of 2019 (1 January 2019) to the third quarter of 2023 (30 September 2023) were extracted from FAERS database, and the adverse events signal intensity was determined using the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayes geometric mean methods. Time-to-onset and univariate logistic regression analysis were performed to describe the characteristics and risk factors of oxaliplatin-associated neurological adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 4,471 cases of oxaliplatin-associated neurological adverse events were identified, with 318 neurological adverse events being documented, among which 87 adverse events satisfied the thresholds of four methodologies. The median time-to-onset of oxaliplatin-associated neurological adverse events was 2 days (interquartile range 0\u201336 days). Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The real-world neurotoxicity spectrum of oxaliplatin and its characteristics and influencing factors were obtained through data mining of FAERS, providing valuable insights for healthcare professionals to effectively manage the risk of neurological adverse events associated with oxaliplatin in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1431579","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:52:42Z","timestamp":1720500762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Xianglin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107905","DOI":"10.1016\/j.neuropharm.2019.107905","article-title":"Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity","volume":"164","author":"Alberti","year":"2020","journal-title":"Neuropharmacology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support. Care Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"643824","DOI":"10.3389\/fmolb.2021.643824","article-title":"Oxaliplatin-induced neuropathy: genetic and epigenetic profile to better understand how to ameliorate this side effect","volume":"8","author":"Branca","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40122-017-0092-3","article-title":"Pain in platin-induced neuropathies: a systematic review and meta-analysis","volume":"7","author":"Brozou","year":"2017","journal-title":"Pain Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1200\/JCO.22.02773","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"41","author":"de Gramont","year":"2023","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2468-1253(22)00044-9","article-title":"Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jdv.19703","article-title":"Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system","volume":"38","author":"Jedlowski","year":"2023","journal-title":"J. Eur. Acad. Dermatology Venereol. JEADV"},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","article-title":"Platinum-induced neurotoxicity: a review of possible mechanisms","volume":"8","author":"Kanat","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","article-title":"Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis","volume":"21","author":"Kanbayashi","year":"2010","journal-title":"Anti-cancer drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00415-020-09942-w","article-title":"Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment","volume":"268","author":"Kang","year":"2021","journal-title":"J. neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1200\/JCO.22.01637","article-title":"Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage III colon cancer: findings from CALGB (alliance)\/SWOG 80702","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"893239","DOI":"10.3389\/fnins.2022.893239","article-title":"Dissociation in neural correlates of hyperactive\/impulsive vs. Inattentive symptoms in attention-deficit\/hyperactivity disorder","volume":"16","author":"Luo","year":"","journal-title":"Front. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110433","DOI":"10.1016\/j.pnpbp.2021.110433","article-title":"Altered cortical activation associated with mirror overflow driven by non-dominant hand movement in attention-deficit\/hyperactivity disorder","volume":"112","author":"Luo","year":"","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/brain\/awac273","article-title":"TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy","volume":"146","author":"Marcotti","year":"2023","journal-title":"Brain J. neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8859","DOI":"10.3390\/ijms23168859","article-title":"Omeprazole suppresses oxaliplatin-induced peripheral neuropathy in a rodent model and clinical database","volume":"23","author":"Mine","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of Life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/c8dt00838h","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"B23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance)","volume":"33","author":"Park","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/ajco.12694","article-title":"Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review","volume":"13","author":"Pulvers","year":"2017","journal-title":"Asia-Pacific J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system","volume":"29","author":"Shu","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","article-title":"Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients","volume":"85","author":"Velasco","year":"2014","journal-title":"J. neurology, Neurosurg. psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","article-title":"Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel","volume":"157","author":"Ventzel","year":"2016","journal-title":"Pain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000443377","article-title":"Prechemotherapy touch sensation deficits predict oxaliplatin-induced neuropathy in patients with colorectal cancer","volume":"90","author":"Wang","year":"2016","journal-title":"Oncology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.17219\/acem\/38154","article-title":"Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer","volume":"24","author":"Wiela-Hoje\u0144ska","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.21.02628","article-title":"Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III achieve trial","volume":"40","author":"Yoshino","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431579\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:52:46Z","timestamp":1720500766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431579\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1431579"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1431579","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"article-number":"1431579"}}